Sherene Loi, MD· @LoiSher · X·· 2 days agoScore90
Body · original
#ESMO2026
Panku-breast01
Izabren sig. improves PFS in met HR+HER2 post CDK4i
#BreastCancer
👏New targets 🎈impressive ORR too
➡️broadly comparable to DB04 - here all HER2
But 🎈haem tox
Still have the what next issue 🤷🏻♀️
Online publication in @TheLancetOncol
#ESMOAmbassadors #bcsm @OncoAlert @myESMO
482 views · 12 likes · 6 reposts · 0 replies
Conference abstracts
LBA50matched by Proffered paper 1: Breast cancer, early and advanced stage
PANKU-Breast01: Randomized phase III study of izalontamab brengitecan (iza-bren) in previously treated unresectable locally advanced or metastatic (LA/M) hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)
https://esmocongress.esmo.orgSource: Sherene Loi, MD · x.com